Related Experiment Video

Updated: Aug 15, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review

Margarite D Matossian1, Carrow I Wells2, William J Zuercher2

  • 1Tulane University School of Medicine, Department of Pharmacology, New Orleans LA, United States.

Current Medicinal Chemistry
|March 22, 2021
PubMed

Insights

Never-in-mitosis kinase 5 (NEK5) is an understudied mitotic kinase. This review explores NEK5

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Mitotic kinases are crucial in cancer development and progression.
  • The Never-in-Mitosis Kinase (NEK) family represents novel therapeutic targets.
  • NEK5, a member of the NEK family, is understudied in cancer biology.

Purpose of the Study:

  • To review the current knowledge on NEK5's role in cancer.
  • To discuss NEK5's implications in tumor development and metastasis.
  • To update on the development of NEK5-targeting agents for cancer therapy.

Main Methods:

  • Literature review of studies on NEK5 in various cancer systems.
  • Summary of research on NEK5 activity in cellular processes.
  • Overview of advancements in developing selective NEK5 inhibitors.

Main Results:

  • Emerging evidence suggests NEK5 has critical functions in solid tumors.
  • NEK5 expression and activity are implicated in tumor growth and metastasis.
  • Recent progress has been made in developing NEK5-specific inhibitors.

Conclusions:

  • NEK5 is a promising, yet understudied, target for cancer therapy.
  • Targeting NEK5 with selective inhibitors holds potential for new cancer treatments.
  • Further research into NEK5 function and inhibition is warranted.
Keywords:
NEK5Never-in-mitosis kinase familybreast cancermetastasis.mitosistherapeutic target

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.6K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...